The Régie de L’assurance Maladie du Québec (RAMQ) formulary (medicament d’exception) in Quebec will add codes for JARDIANCE® (empagliflozin), SYNJARDY® (a single-pill combination of empagliflozin and metformin), and TRAJENTA® (linagliptin), making them more easily available for patients with type 2 diabetes, and continuing the public funding for the medicines.
The medicines are covered by public prescription insurance plans, but access to the drugs was not straightforward without the addition of the specific coding. Mr Pierre Blain, CEO of Les Usagers de la Santé du Québec said of the move:
“The addition of new codes for JARDIANCE®, SYNJARDY® and TRAJENTA® to RAMQ is great news for all people with type 2 diabetes in Quebec. The inclusion of codes in RAMQ’s list of ‘Exceptional Medications’ means that patients will have better access to innovative treatments, reducing the administrative burden related to reimbursement.”